World Bank Opposes Vaccine Intellectual Property Waiver As WTO Talks Resume
The World Bank's concern has come out of concern that it would hamper innovation in the pharmaceuticals sector.
World Bank President David Malpass said on Tuesday the bank does not support waiving intellectual property rights for COVID-19 vaccines at the World Trade Organization out of concern that it would hamper innovation in the pharmaceuticals sector.
His comments on the subject, made during a call with reporters on World Bank economic forecasts, came as WTO negotiations over the proposed waiver resumed in Geneva.
Asked whether he backs a WTO vaccine IP waiver, which India, South Africa and other emerging market countries argue is needed to expand vaccine access, Malpass said: "We don't support that, for the reason that it would run the risk of reducing the innovation and the R&D in that sector."
The comment puts Malpass, a Trump administration nominee, at odds with the Biden administration, which is supporting text-based WTO negotiations for vaccine intellectual property rights, led by U.S. Trade Representative Katherine Tai.
Major vaccine makers and the pharmaceutical industries have opposed the waiver from the WTO's agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS), arguing that it would stifle innovation and do little to effectively increase vaccine supplies constrained by trade barriers, shortages of components and a lack of manufacturing capabilities.
Malpass on Tuesday reiterated his calls for wealthy countries to quickly donate their excess vaccine doses to the developing world as quickly as possible.
The World Bank said its global growth forecasts, raised to 5.6% for 2021 and 4.3% for 2022, could be higher if vaccinations can be accelerated in developing countries.
In Geneva, negotiations were proceeding on Tuesday and Wednesday over revised waiver proposals from India and South Africa that remained far broader than the narrow vaccine-only waiver favored by USTR Tai.
"It seems to be they are still far apart. Their positions have not fundamentally changed," a Geneva-based trade official told Reuters.
His comments on the subject, made during a call with reporters on World Bank economic forecasts, came as WTO negotiations over the proposed waiver resumed in Geneva.
Asked whether he backs a WTO vaccine IP waiver, which India, South Africa and other emerging market countries argue is needed to expand vaccine access, Malpass said: "We don't support that, for the reason that it would run the risk of reducing the innovation and the R&D in that sector."
The comment puts Malpass, a Trump administration nominee, at odds with the Biden administration, which is supporting text-based WTO negotiations for vaccine intellectual property rights, led by U.S. Trade Representative Katherine Tai.
Major vaccine makers and the pharmaceutical industries have opposed the waiver from the WTO's agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS), arguing that it would stifle innovation and do little to effectively increase vaccine supplies constrained by trade barriers, shortages of components and a lack of manufacturing capabilities.
Malpass on Tuesday reiterated his calls for wealthy countries to quickly donate their excess vaccine doses to the developing world as quickly as possible.
The World Bank said its global growth forecasts, raised to 5.6% for 2021 and 4.3% for 2022, could be higher if vaccinations can be accelerated in developing countries.
In Geneva, negotiations were proceeding on Tuesday and Wednesday over revised waiver proposals from India and South Africa that remained far broader than the narrow vaccine-only waiver favored by USTR Tai.
"It seems to be they are still far apart. Their positions have not fundamentally changed," a Geneva-based trade official told Reuters.
AI Disclaimer: An advanced artificial intelligence (AI) system generated the content of this page on its own. This innovative technology conducts extensive research from a variety of reliable sources, performs rigorous fact-checking and verification, cleans up and balances biased or manipulated content, and presents a minimal factual summary that is just enough yet essential for you to function as an informed and educated citizen. Please keep in mind, however, that this system is an evolving technology, and as a result, the article may contain accidental inaccuracies or errors. We urge you to help us improve our site by reporting any inaccuracies you find using the "Contact Us" link at the bottom of this page. Your helpful feedback helps us improve our system and deliver more precise content. When you find an article of interest here, please look for the full and extensive coverage of this topic in traditional news sources, as they are written by professional journalists that we try to support, not replace. We appreciate your understanding and assistance.
